Abstract
Recent randomized, controlled trials suggest that B-cell-depletion therapy with rituximab effectively induces remission in anti-neutrophil-cytoplasmic-antibody-associated vasculitis but is ineffective in patients with lupus nephritis or nonrenal systemic lupus erythematosus with moderate-to-severe disease activity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
